Investor CR Group L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by CR Group L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2024-05-13 13D/A TTOO / T2 Biosystems, Inc. 8,853,173 10,677,973
2024-05-07 13D/A TTOO / T2 Biosystems, Inc. 4,104,838 8,853,173
2024-04-19 13D TTOO / T2 Biosystems, Inc. 4,104,838
2024-03-15 13G/A AVGR / Avinger, Inc. 150,545
2023-08-14 13G/A US0537348858 / AVINGER INC 2,684,160
2023-07-13 13G US89853L2034 / T2 Biosystems Inc 72,503,592
2021-01-06 13G/A ASRT / Assertio Holdings, Inc. 6,291,148 291,148
2020-12-30 13G/A ASRT / Assertio Holdings, Inc. 6,291,148
2020-06-09 13D/A 878193101 / TearLab Corp 11,850,131 11,850,131
2020-05-22 13D/A ZCOR / Zyla Life Sciences 7,023,333 0
2020-05-21 13D 878193101 / TearLab Corp 11,850,131
2020-03-26 13D/A ZCOR / Zyla Life Sciences 7,023,333
2020-02-13 13G AVGR / Avinger, Inc.
2020-02-13 13G VIVE / Viveve Medical, Inc.
2019-10-02 13D/A VLRX / Valeritas, Inc. 52,685,969 17,459,878
2019-07-03 13D/A ZCOR / Zyla Life Sciences 7,023,333
2018-12-28 13G SBBP / Strongbridge Biopharma plc 2,729,267
2018-11-21 13D/A VLRX / Valeritas, Inc. 7,685,969 52,685,969
2017-04-07 13D VLRX / Valeritas, Inc. 7,685,969